Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 8/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | AOC2 | O75106 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420363 | 1.00 | FEN1 (0.33) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15420540 | 1.00 | FEN1 (0.33) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL12987272 | 0.91 | GRM5 (0.35) | FEN1ALOX5APSMOGRM2AOC2 | |
| SCHEMBL15441453 | 0.91 | GRM5 (0.35) | FEN1ALOX5APSMOGRM2AOC2 | |
| SCHEMBL12987399 | 0.91 | SMO (0.40) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15420745 | 0.91 | SMO (0.40) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15420466 | 0.91 | SMO (0.40) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15441494 | 0.90 | SMO (0.34) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15419974 | 0.90 | SMO (0.34) | FEN1ALOX5APTRPV4KCNH2GPR119 | |
| SCHEMBL15420401 | 0.84 | KCNH2 (0.38) | KCNH2GPR119GRM4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | FEN1 4789/4885ALOX5AP 1539/4885TRPV4 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.